Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Bgt-226 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 13/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | TP53RK | Q96S44 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.90 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.90 |
| ▸ | RIOK2 | Q9BVS4 | 7/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgt-226 Free Base SCHEMBL29351405 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29388607 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29388241 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL31326455 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL29394351 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL996047 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| Bgt-226 Free Base SCHEMBL996046 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL24455231 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL20548306 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDCSNK2A2FECH | |
| SCHEMBL928275 | 0.92 | MTOR (0.86) | MTORPIK3CAPIK3CDCSNK2A2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 942 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | SOVARGEN CO., LTD. (KR) | 2025-10-28 | — | — | US | claimed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| US-20100196365-A1 | USE OF IMIDAZOQUINOLINES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | claimed |
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| EP-2129379-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | Novartis AG (CH) | 2009-12-09 | — | — | EP | claimed |
| WO-2009118324-A1 | 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| WO-2008103636-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | MTOR, ULK1, RICTOR | MTOR 1/4885PIK3CA 34/4885PIK3CD 35/4885 |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 347/4885PIK3CD 100/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | MTOR 4538/4885PIK3CA 2438/4885PIK3CD 2996/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-20100196365-A1 | USE OF IMIDAZOQUINOLINES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS | EGFR, ERBB2, ERBB4 | MTOR 1098/4885PIK3CA 676/4885PIK3CD 1453/4885 |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 358/4885PIK3CD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.